Study summary
Two-target CAR T cells showed durable activity in recurring glioblastoma
12.0 momedian survival in recurrent glioblastoma
What was tested
CAR T cells engineered to attack two tumor targets (EGFR and IL-13Rα2), infused into the brain fluid, for glioblastoma that came back after treatment.
What they found
- Median survival was 12.0 months; 28% were alive at 18 months.
- One person had a partial response still ongoing at 33 months.
- Brain inflammation was common early on but no delayed side effects were seen.
What it means
Encouraging for a cancer where survival after relapse is usually under a year. Larger trials are needed.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.